Kornimate/medical-research-clean huggingface dataset:
cognitive effects of immunomodulatory drugs in ms

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to examine and compare changes in the specific thinking skills of patients with rrms who are receiving treatment with one of three immunomodulatory medications (avonex, copaxone, or rebif).

in addition this study will compare the patients' personal view of how they are doing, any changes in physical disability, and the frequency and severity of relapses over the three year period.

Eligibility criteria:
inclusion criteria: * diagnosis of rrms for at least one year, * currently on one of three immunomodulatory drugs (avonex, copaxone, or rebif), * visual acuity is 20/50 or better, * patient has four color vision, * must have at least a high school education exclusion criteria: * history of head injury, drug/alcohol abuse, and/or psychiatric problems, -current diagnosis of a severe or lifethreatening disease other than ms, * currently taking immunosuppressant medication, * resides greater than 200 miles from the study site
hpv message testing and social media campaign

Conditions: Vaccine; Human Papilloma Virus

Summary: this project involves a social media campaign to increase parent's knowledge and acceptance of the hpv (human papillomavirus) vaccine. the current vaccine protects against nine types of hpv, including seven that are known to cause cancer. the centers for disease control and prevention (cdc) estimates that the current hpv vaccine could prevent 90% of cancer cases caused by hpv, including cases of cervical cancer, oropharyngeal (mouth and throat) cancer, anal cancer, and others. about 150 and 104 cases of hpv-associated cancers are diagnosed each year in new hampshire and vermont, respectively-many of which could be prevented through vaccination. currently, only 49.8% of new hampshire adolescents and 44.3% of vermont adolescents were not up-to-date for hpv vaccination as of 2016. this social media campaign is testing a set of campaign messages with parents locally and nationally to see which messages are most effective in improving their knowledge and acceptance of the vaccine. a study survey link will monitor the number of people reached and will measure parental intention to get their children vaccinated against hpv.


Eligibility criteria:
inclusion criteria: * parents of children 9-14 years old exclusion criteria: * non-parents

Keywords: adolescence attitudes parents vaccination
the surrogate project (surrogate storytelling)

Conditions: Surrogate Decision Maker, After Death of Patient

Summary: research protocol abstract: this is a phase ii controlled trial (rct) of a "storytelling" intervention compared to no treatment among surrogates who have participated in a decision to limit life-sustaining treatment in the icu for an incapacitated loved one. subjects will be sequentially assigned to "storytelling" (a facilitated elicitation of the experience 2-4 weeks after bereavement) or no treatment with follow up "monitoring of well-being". subjects will receive print bereavement brochures at 1 week, and undergo telephone symptom assessment at 2-weeks, 3-months, and 6-months after bereavement.


Eligibility criteria:
inclusion criteria: screening/re-contact (1st phase) * eligible patients will: * lack decision-making capacity * have a surrogate decision maker (family member or friend) eligible surrogates will: * be 18 years of age or older * self-identify as having primary decision-making authority for the patient * live within approximately 50miles or less of the university of pittsburgh * be able to conduct a 1hr interview in english * court-appointed power of attorney will be excluded, as they are not expected to experience the same emotional distress as a family member or friend of a critically ill patient. for assignment to intervention/control (2nd phase) * eligible surrogates will: * have previously given consent for study staff to follow their loved one's course in the hospital and to be re-contacted * have participated in decision making about limitation of life-sustaining treatments (lst) for their loved one (icu patient) * have had their loved one (icu patient) die in the hospital exclusion criteria: screening/re-contact * ineligible patients will: * be less than 18 years old * prisoners * be of other legal concern, such as malpractice * ineligible surrogates will: * be less than 18 years old * be unable to complete a 1-hour interview and questionnaires in english * for assignment to intervention/control ineligible patients will: * have fully and permanently regained decision-making capacity and therefore no longer require a surrogate to make treatment decisions * be discharged from hospital alive

Keywords: intensive care unit patients and families surrogate decision making life sustaining treatments (lst)
a future thinking intervention for comorbid tobacco use disorder and bipolar disorder

Conditions: Bipolar Disorder; Tobacco Use Disorder

Summary: future self-bd is a 6-session virtual intervention that encourages participants to vividly generate personal and positive future events that they anticipate may be benefited by smoking cessation. each session will be conducted on hipaa-compliant zoom and led by the pi (dr. gold).

this is a treatment development study that begins with an open non-randomized pilot trial (n = 10) in which we will test the manual developed for future self-bd by assessing the acceptability and feasibility of future self-bd. after completion of the non-randomized pilot trial and subsequent revisions to the future self-bd manual, we will conduct a parallel randomized controlled trial comparing future self-bd (n = 30) to a control treatment, daily check-ins (n = 30). future self-bd and daily check-ins involve six, weekly, 1.5-2 hour sessions and one 1.5 hour follow-up session one month after completion of the sixth session; thus, participants will be enrolled in the study for a period of 10 weeks. assessments will occur at all study sessions.

Eligibility criteria:
inclusion criteria: * adults aged 18 or older * have a diagnosis of bd i or ii * have a diagnosis of tobacco use disorder * be engaged in outpatient treatment with a medical provider * be on a stable dose of a mood-stabilizing medication * smoke an average of at least 5 cigarettes per day for the past 30 days at baseline (based on the heaviness of smoking index(heatherton et al., 1989)) * be interested in quitting smoking * not currently or in the past 3 months be receiving smoking cessation treatment. exclusion criteria: * current psychosis * intent to harm oneself with an associated plan and intent to act on suicidal thoughts * experiencing severe symptoms of depression and/or hypomania that may warrant a higher level of care (a patient health questionnaire-9 total score ≥ 20(kroenke et al., 2001) and/or an altman self-rating mania scale total score ≥ 6(altman et al., 1997) will trigger further clinician evaluation)

Keywords: bipolar disorder comorbid tobacco use disorder smoking cessation
unilateral tap block vs trocar insertion sites infiltration anesthesia in laparoscopic cholecystectomy

Conditions: Biliary Disease

Summary: laparoscopic cholecystectomy is a commonly performed operation in general surgery practice. peripheral nerve block methods commonly used for analgesia after this operation are: transversus abdominis plane block (tap) and trocar insertion sites local anesthetic infiltration anesthesia in this study, we aimed to compare these methods in terms of postoperative analgesia, nausea-vomiting and patient satisfaction

patients will be randomly allocated by a computer generated random numbers list into three groups. after general anesthesia induction and intubation patients will receive analgesia according to group allocation. in group tap (group t) the transversus abdominis plane block will be commenced with ultrasound guidance while the patients is in the supine position with a subcostal approach using 20 ml 0.25% bupivacaine and 21 g block needle. in group infiltration anesthesia (group i) the trocar insertion sites will be infiltrated with 20 ml 0.25% bupivacaine: 7 ml for the 10 mm trocar insertion sites and 3 ml for the 5 mm trocar insertion sites. the control group (group c) will not receive any local anesthetic. all patients will receive rescue analgesia with intravenous patient controlled analgesia with tramadol (20 mg bolus dose and 20 minutes lockout time) postoperative pain will be assessed during resting and coughing with a numeric pain scale (nrs) and nausea and vomiting with a postoperative nausea vomiting score at the postoperative 1, 3, 6, 12. and 24 hours. the amount of tramadol consumed in the postoperative period will be recorded. patient satisfaction will be assessed with the likert scale at postoperative 24 hours.

Eligibility criteria:
inclusion criteria: • clinical diagnosis of biliary disease exclusion criteria: * uncooperative patients * blood coagulation disorders * laparatomy * obesity: body mass index \>35 * renal failure * hepatic failure * emergency surgery * pregnancy

Keywords: unilateral transversus abdominal plane block local infiltration anesthesia cholecystectomy postoperative analgesia
validation of cognitive screenings for the hearing impaired

Conditions: Dementia; Hearing Loss; Auditory Processing Disorder

Summary: there are currently no cognitive tests that have been validated as screening tools for people with dementia and comorbid hearing loss. this is particularly important given the high prevalence of hearing impairment in older adults presenting to memory services and the risk of misdiagnosis of dementia in this population as outlined above. cognitive tests validated in hearing impaired populations will also be important as outcome tools for interventional research aiming to find out if treating hearing loss may reduce dementia risk in the longer term.

hearing loss is very prevalent in older population. this leads to further problems such as communication problem, isolation from the community and depression. moreover, hearing impairment may potentially affect the patients' cognitive function as demonstrated in the above mentioned published papers. communication problems that arise from a hearing loss alone can also interfere with administration of cognitive test battery, as a previous study showed that re-administered of mmse test with assistive listening device can immediately improve the test score among elderly (1). therefore, special adaptation of the cognitive test battery to address the needs of hearing impaired older adult is necessary. this is to ensure that the test result reflects the exact cognitive state of the older adult with hearing impairment, not effected by hearing loss. moreover, appropriate cut-off point scores for hearing impaired population should be identified for these new cognitive screening tools. this is to ensure appropriate referral for further diagnosis and prompt management for cognitive impairment/dementia among older adults with hearing loss. in addition, since hearing loss can potentially lead to deterioration in patients' cognitive function over time (2). follow up assessments of cognitive function among older adults with hearing impairment can determine the rate of deterioration in retrospective trial(2). this prospective trial follow up of cognitive function among hearing loss participants may uncover additional risk factors associated with the deterioration. better understanding of these risk factors can potentially lead to further intervention in order to delay decline in patients' cognitive function.

Eligibility criteria:
inclusion criteria: * age over 65 years * documented hearing loss (currently wearing hearing aids and/or hearing testing with a hearing average of \>/= 30db hl in d-hi,mci-hi group) exclusion criteria * uncorrected visual impairment; cognitive and/or physical disability(s) which prevent the performance of the written/drawing elements of the tests, in the opinion of the researcher. * severe to profound hearing loss (pta \>70dbhl)

Keywords: dementia hearing loss auditory process
evaluation of fluid retention due to superpotent topical corticosteroid

Conditions: Bullous Pemphigoid

Summary: clinical observation frequently shows a paradoxical effect of topical corticosteroids in charge of a sudden melting of edema in the first days of treatment, which could be due to mobilization of extracellular. no study has shown the value of this measure in patients treated with topical steroids. this uncertainty, coupled with the observation of the paradoxical effects of topical steroids on edema are some patients that despite the systemic absorption of clobetasol propionate, a salt-free diet is not currently recommended practice.

the main objective of the study is to evaluate whether there is fluid retention after introduction of clobetasol propionate treatment from 10 g/day dosage to 40 g / day in patients with bullous pemphigoid. bio-impedance is a noninvasive device for measuring with an electric current of low intensity the different volumes of the human body. a preliminary experiment of impedance measurements in some patients with bullous pemphigoid (examination requested as part of a nutritional assessment) showed that these patients had mostly a total water loss without dehydration, corresponding to a significant undernutrition during 1 month of treatment, possibly related to muscle wasting and protein loss by skin erosions without obvious argument for fluid retention, justifying reproduce these measures on a larger number of patients and the other to accurately assess the evolution of nutritional parameters during the first month of treatment.

Eligibility criteria:
inclusion criteria: * patient with age higher than 18 * patient with bullous pemphigoid, * patient treated by local corticosteroid therapy (clobetasol propionate cream) but not yet processed or for less than 48 hours, * signed informed consent. * patient affiliated to social security regimen * effective contraception in women of childbearing age (for postmenopausal women, confirmatory diagnosis of menopause will be collected) exclusion criteria: * concomitant treatment with corticosteroids * recent introduction or recent (\<6 weeks) treatment with diuretics, angiotensin-converting enzyme, receptor antagonist or anti-angiotensin renin (aliskiren) * contraindication to the use of clobetasol propionate (dermoval and clarelux) * patient on salt diet (\<or = to 5 g / d) * patients carry a defibrillator or a pace maker * amputated patient * pregnant and lactating * patient with urinary incontinency * recent heart decompensation in the last 6 weeks * known nephrotic syndrome * known or severe hepatic impairment * hypoalbuminaemia less than 20 g / l
comparing the effectiveness of traditional physiotherapy combined with virtual reality for post-stroke patients

Conditions: Stroke

Summary: this study aims to evaluate the effectiveness of combining virtual reality (vr) therapy with traditional physiotherapy in post-stroke rehabilitation. post-stroke patients often suffer from impairments in motor function, balance, and overall quality of life. while traditional physiotherapy is a widely accepted method for stroke recovery, incorporating vr technology may enhance treatment outcomes by providing an engaging, immersive environment that motivates patients to perform therapeutic movements.

this study will compare the functional and quality-of-life improvements in patients undergoing traditional physiotherapy alone versus those receiving a combination of conventional physiotherapy and vr interventions. by assessing changes in motor function, trunk stability, balance, and quality of life, this research will provide valuable insights into whether vr can be an effective adjunctive tool in post-stroke rehabilitation programs.

Eligibility criteria:
inclusion criteria: * stroke, either ischemic or hemorrhagic * participants who can ambulate independently or with minimal assistance. * participants who were willing \& able to adhere to the study protocol. * including participants who were attending follow-up appointments \& completing outcome measures. * participants who were able to understand \& provide written informed consent exclusion criteria: * existence of additional neurological disorders (such as multiple sclerosis or parkinson's disease) or serious medical conditions that could prevent participants from participating in the study. * participants receiving rehabilitation or rigorous physical treatment in the previous three months were excluded. * pregnant women or breastfeeding women. * participants who refused to participate in the study or provide informed consent.
aml2003 - standard-therapy vs intensified therapy for adult acute myeloid leukemia patients <= 60 years

Conditions: Leukemia, Nonlymphocytic, Acute

Summary: aml2003 is a prospective randomized trial, to investigate the value of early allogeneic stem cell transplantation in aplasia after induction therapy for high risk patients with acute myeloid leukemia.

aml2003 is a prospective randomized trial, to investigate the value of early allogeneic stem cell transplantation in aplasia after induction therapy for high risk patients with acute myeloid leukemia. a rapid analysis of risk-factors (cytogenetics, flt3 status, clearance of blasts after first induction) and the donor situation is of utmost importance. for this "fast search" diagnostic, which is accomplished in all enclosed patients, significant resources are provided, to take the load off the participating centers. furthermore, the relevance of autologous transplantation and the benefit of additional substances within the postremission therapy such as m-amsa or mitoxantrone will be investigated. there is an up-front randomisation in four therapy arms with two cross-classifying factors of two stages (intensified vs. standard therapy and ara c vs. ara c+ mitoxantrone + m-amsa). thus, the intergroup treatment schedule of the german competence network is integrated into the aml2003 study as a central element and 25% of the patients are treated accordingly. in the intensified therapy arms a risk-adapted and priority-based therapy is implemented, including early allogeneic and consolidating autologous stem cell transplantation, respectively. in addition to the clinical questions , a detailed concomitant research program was initiated for the aml2003 study, to get a better view of the heterogeneity of aml and to open new ways for "custom-made" therapies.

Eligibility criteria:
inclusion criteria: * de novo or secondary acute myeloid leukemia fab-subtypes m0-m2 and m4-m7 * de novo or secondary myelodysplastic syndrome who-type raeb-2 * age 16 to 60 years * written informed consent exclusion criteria: * severe comorbidities * severe, uncontrolled complications of the leukemia * prior therapy for aml/mds * other simultaneous hematological malignancies * hiv-infection * known allergies against study medication * pregnancy * missing written informed consent

Keywords: acute myeloid leukemia risk adapted treatment early allogeneic stem cell transplantation autologous stem cell transplantation
children rehydration during exercise

Conditions: Dehydration in Children

Summary: the low fluid intake in combination with a high intake of sugar-sweetened beverages (ssb) by children is a significant concern among public health professionals. therefore reformulation of existing commercially available beverages has been suggested as one of the strategies to change ssb beverage behaviors of children. it has been suggested that lack of flavor in plain water is one of the factors of low water intake in children. therefore, the addition of a flavor to a low-carbohydrate beverage might increase and facilitate the voluntary fluid intake in children, and result in more effective rehydration during and after exercise. the present study aims to examine if a lower sugar flavored water will improve voluntary hydration in children that perform multiple exercise bouts within a period of 3 hours.

subject will enter a warm room with a temperature between 28-30°c (80-85°f). then, subjects will undergo a 3-hour walk, cycle, and rest protocol. the exercise intensity is based on 70% of the subject's predicted heart rate using the formula: 220 beats per minute (bpm) - 10 years of age = 210 bpm, and 70% equals 147 bpm). this is an intensity in which the subject has an elevated breathing frequency but can still talk. during the 3-h period subject will complete the following one-hour test three times: * 10 min walking on the treadmill at 70% of predicted max heart rate (\~147 bpm) * 5 min rest * 10 min cycling on the cycle ergometer at 70% of predicted max heart rate (\~147 bpm) * 35 min rest during the 3-h period, subjects will have free access to fluids body weight and urine samples will be collected during the experiement

Eligibility criteria:
inclusion criteria: * girls and boys age 8 to 10 years * willing to walk and cycle in a warm environment (80-85°f) * body weight ≤85th percentile for their age group exclusion criteria: * history of conditions known to alter body water balance (diabetes, renal disease, etc.) * drugs that (may) influence hydration status (including selective serotonin reuptake inhibitor (ssri), adhd medication, diuretics and corticoids) * physical or mental disabilities that would prevent participation in moderate-intensity treadmill walking/jogging and cycling * previous diagnosis of heat stroke * body weight ≥86th percentile for their age group
safety study of ipi-504 in patients with gastrointestinal stromal tumors (gist) or soft tissue sarcomas (sts)

Conditions: Gastrointestinal Stromal Tumors; Soft Tissue Sarcomas

Summary: the primary objectives of the study are: * determine the safety and maximum tolerated dose (mtd) of ipi-504 in gist and sts patients who have failed prior therapies * recommend a dose for subsequent studies of ipi-504

ipi-504 is a novel, water-soluble analog of 17-aag and a potent inhibitor of hsp90. hsp90's role in the cell is to control the proper folding, function, and viability of various "client" proteins. many of these client proteins (such as akt, her-2, bcr-abl, pdgfr-α, and c-kit) are oncoproteins or important cell signaling proteins. in patients with gist, mutations in the tyrosine kinase receptor kit play a critical role in the pathogenesis of this disease. inhibition of kit signaling with the tyrosine kinase inhibitor imatinib (im) is a very effective treatment for gist patients. however, new mutations arise in kit conferring resistance to im treatment which results in disease progression. kit is a client protein of hsp90 and is sensitive to ipi-504. in soft tissue sarcomas, there may be genetic abnormalities that lead to the expression of certain proteins that drive the growth of cancer. these cancer-driving proteins may be stimulated by hsp90. this provides a scientific rationale for phase 1 clinical testing of ipi-504 in patients with advanced gist and sts who have failed prior therapies.

Eligibility criteria:
inclusion criteria: * pathologically confirmed diagnosis of gist or sts * failed prior therapies * ecog performance status of 0-2 * ability to adhere to the study visit schedule and all protocol requirements exclusion criteria: * previous treatment with 17-aag, dmag, or other known hsp90 inhibitor * participation in any investigational drug study or treatment with any other kinase inhibitor therapy within 2 weeks preceding start of treatment * concurrent radiation therapy is not permitted * concurrent treatment with any agent that alters cyp3a activity * concurrent treatment with any agent that may prolong the qtc interval * myocardial infarction or active ischemic heart disease within 6 months * history of arrhythmia * baseline qtc \>450 * grade 3 or greater peripheral neuropathy * renal insufficiency, serum creatinine \>1.5 x uln * platelets \< 100,000 mm3 * ast and / or alt \> 2.5 x uln * anc \<1,500 cells/mm3 * alkaline phosphatase \> 2.5 x uln * amylase and lipase \> 1.5 x uln * hemoglobin \< 9.0 g/dl